Evidence map›Paper›PMID 36276147›Full record

ReviewFrontiers in oncology2022

The complex interactions between the cellular and non-cellular components of the brain tumor microenvironmental landscape and their therapeutic implications.

Syed M Faisal, Andrea Comba, Maria L Varela, Anna E Argento, Emily Brumley, Clifford Abel, Maria G Castro, Pedro R Lowenstein

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Current issues in molecular biology · 2026
    Article
  9. Review
  10. Review
  11. Review
  12. Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Microenvironmental Drivers of Glioma Progression.International journal of molecular sciences · 2025
    Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Syed M FaisalDept. of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States.
Andrea CombaDept. of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States.
Maria L VarelaDept. of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States.
Anna E ArgentoDept. of Biomedical Engineering, University of Michigan, Ann Arbor, MI, United States.
Emily BrumleyDept. of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States.
Clifford AbelDept. of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States.
Maria G CastroDept. of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States.
Pedro R LowensteinDept. of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States.
University of Michigan–Ann Arbor · US

Funding

Role of EZH2 in Breast Cancer ProgressionR01CA107469 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Celina G Kleer · 2005 to 2026
$5.9M
Oligodendrocyte-focused rAAV gene therapy strategies for Canavan disease and LeukodystrophiesR01NS076991 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Guangping Gao · 2012 to 2026
$5.7M
Role of CCN6 (WISP3) in the Progression and Metastasis of Breast Cancer.R01CA125577 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Celina G Kleer · 2008 to 2026
$5.5M
Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic StrategiesR37NS094804 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2015 to 2021
$2.9M
Novel combined immunotherapeutic strategies for glioma: using pet dogs as a large animal spontaneous modelU01CA224160 · NCI · UNIVERSITY OF MINNESOTA · PI PLUHAR, GRACE ELIZABETH · 2017 to 2021
$2.7M
The Role of Collagen and its Signaling Mechanisms in Glioma Progression and Invasion.R01NS122234 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Pedro R. Lowenstein · 2022 to 2026
$2.4M
Neuroimmunology of Malignant Brain Tumors: Innate MechanismsR01NS096756 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOWENSTEIN, PEDRO R. · 2016 to 2020
$2.1M
Crosstalk between glioma cells & immune cells in the tumor microenvironment: TherR01NS074387 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2011 to 2015
$1.9M
Role of the collagen receptor LAIR-1 in glioma progression and the tumor immune microenvironmentR01NS127378 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Pedro R. Lowenstein · 2022 to 2026
$1.8M
Mechanisms of glioma growth and invasion novel therapeutic strategiesR01NS082311 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOWENSTEIN, PEDRO R. · 2013 to 2017
$1.7M
Tuning Biomaterials-immune cell interactions for treatment of glioblastoma multiformeR01EB022563 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOON, JAMES J. · 2016 to 2019
$1.7M
Immune-mediated therapies in a genetically engineered murine model of diffuse intrinsic pontine gliomaR21NS107894 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G · 2019 to 2019
$442k
NCI NIH HHS R01 CA107469NCI NIH HHS R01 CA125577NCI NIH HHS U01 CA224160NIBIB NIH HHS R01 EB022563NINDS NIH HHS R01 NS074387NINDS NIH HHS R01 NS076991NINDS NIH HHS R01 NS082311NINDS NIH HHS R01 NS096756NINDS NIH HHS R01 NS122234NINDS NIH HHS R01 NS127378NINDS NIH HHS R21 NS091555NINDS NIH HHS R21 NS107894NINDS NIH HHS R37 NS094804
6 · The paper itself

Abstract

Glioblastoma (GBM), an aggressive high-grade glial tumor, is resistant to therapy and has a poor prognosis due to its universal recurrence rate. GBM cells interact with the non-cellular components in the tumor microenvironment (TME), facilitating their rapid growth, evolution, and invasion into the normal brain. Herein we discuss the complexity of the interactions between the cellular and non-cellular components of the TME and advances in the field as a whole. While the stroma of non-central nervous system (CNS) tissues is abundant in fibrillary collagens, laminins, and fibronectin, the normal brain extracellular matrix (ECM) predominantly includes proteoglycans, glycoproteins, and glycosaminoglycans, with fibrillary components typically found only in association with the vasculature. However, recent studies have found that in GBMs, the microenvironment evolves into a more complex array of components, with upregulated collagen gene expression and aligned fibrillary ECM networks. The interactions of glioma cells with the ECM and the degradation of matrix barriers are crucial for both single-cell and collective invasion into neighboring brain tissue. ECM-regulated mechanisms also contribute to immune exclusion, resulting in a major challenge to immunotherapy delivery and efficacy. Glioma cells chemically and physically control the function of their environment, co-opting complex signaling networks for their own benefit, resulting in radio- and chemo-resistance, tumor recurrence, and cancer progression. Targeting these interactions is an attractive strategy for overcoming therapy resistance, and we will discuss recent advances in preclinical studies, current clinical trials, and potential future clinical applications. In this review, we also provide a comprehensive discussion of the complexities of the interconnected cellular and non-cellular components of the microenvironmental landscape of brain tumors to guide the development of safe and effective therapeutic strategies against brain cancer.

Indexed as

2HGcellular biomechanicscollagencytokinesECMexosomesGBM

Identifiers

PMID36276147
PMCPMC9583158
OpenAlexW4302287273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.